Stella Xu Net Worth

The estimated Net Worth of Stella Xu is at least $1.73 Million dollars as of 13 May 2019. Stella Xu owns over 125,000 units of Nextcure Inc stock worth over $1,490,040 and over the last 7 years he sold NXTC stock worth over $0. In addition, he makes $241,968 as Independent Director at Nextcure Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Stella Xu NXTC stock SEC Form 4 insiders trading

Stella has made over 1 trades of the Nextcure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 125,000 units of NXTC stock worth $1,875,000 on 13 May 2019.

The largest trade he's ever made was buying 125,000 units of Nextcure Inc stock on 13 May 2019 worth over $1,875,000. On average, Stella trades about 17,857 units every 0 days since 2018. As of 13 May 2019 he still owns at least 1,103,570 units of Nextcure Inc stock.

You can see the complete history of Stella Xu stock trades at the bottom of the page.

Stella Xu biography

Dr. Stella Xu Ph.D. serves as Independent Director of the Company. Dr. Xu has served as Managing Director of Quan Capital, a life sciences venture fund with officers in China and the United States, since August 2017. Prior to joining Quan Capital, Dr. Xu served as Vice President and site head of Roche Innovation Center Shanghai, and a member of the global management team for Roche's Immunology, Inflammation & Infections Diseases Discovery and Translation Area, from September 2012 to August 2017. Dr. Xu joined Roche from McKinsey & Company. Dr. Xu has served as a director of Centrexion Therapeutics Corporation, a biopharmaceutical company focused on the treatment of chronic pain, since January 2018, a director of Tempest Therapeutics, Inc., a clinical stage biotech company advancing small molecule cancer therapeutics, since February 2018, a director of Zidan Medical, Inc., a medtech start-up focusing on early stage lung cancer, since November 2018 and a director of Walking Fish Therapeutics, Inc., an early-stage biotech company, since June 2019. Dr. Xu previously served as a director of ARMO BioSciences, Inc., a publicly traded late-stage biopharmaceutical company focused on immuno-oncology, from August 2017 to July 2018 when it was acquired by Eli Lilly and Company. Dr. Xu received a B.S. in biophysics from Peking University and a Ph.D. in immunology from Northwestern University.

What is the salary of Stella Xu?

As the Independent Director of Nextcure Inc, the total compensation of Stella Xu at Nextcure Inc is $241,968. There are 12 executives at Nextcure Inc getting paid more, with Steven Cobourn having the highest compensation of $993,341.

How old is Stella Xu?

Stella Xu is 49, he's been the Independent Director of Nextcure Inc since 2018. There are 20 older and 1 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.

What's Stella Xu's mailing address?

Stella's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.

Insiders trading at Nextcure Inc

Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong, and Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.

What does Nextcure Inc do?

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col

Complete history of Stella Xu stock trades at Nextcure Inc

Nextcure Inc executives and stock owners

Nextcure Inc executives and other stock owners filed with the SEC include:

• Steven Cobourn,
  Chief Financial Officer
• Michael S. Richman MSBA,
  Co-Founder, CEO, Pres & Director
• Michael S. Richman,
  Co-Founder, CEO, Pres & Director
• Michael Richman,
  President, Chief Executive Officer, Director
• Sol Langermann,
  Chief Scientific Officer
• Dr. Solomon Langermann Ph.D.,
  Chief Scientific Officer
• David Kabakoff,
  Independent Chairman of the Board
• Stephen Webster,
  Independent Director
• Briggs Morrison,
  Independent Director
• Timothy Mayer,
  Chief Operating Officer
• Chau Khuong,
  Independent Director
• Elaine Jones,
  Independent Director
• Stella Xu,
  Independent Director
• John Houston,
  Director
• Garry Nicholson,
  Independent Director
• Linda Liu,
  Senior Vice President - Research
• James Bingham,
  Chief Development Officer
• Sourav Kundu Ph.D.,
  Sr. VP of Devel. & Manufacturing
• Dr. Han Myint FACP, M.D.,
  Chief Medical Officer
• Dr. Timothy Mayer Ph.D.,
  Chief Operating Officer
• Steven P. Cobourn CPA, CPA,
  Chief Financial Officer
• Dr. Lieping Chen M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Kevin N. Heller,
  Chief Medical Officer
• Venture Partners Ix, L.P.So...,
  
• Advisors Llc Orbi Med Capit...,
  
• X L.P.Canaan Partners X Llc...,
  
• Timothy M Shannon,
  Director
• Judith Li,
  Director
• Anne Elizabeth Borgman,
  
• Ellen Feigal,
  
• Sourav Kundu,
  Sr VP, Dev. & Mfg.
• Han Myint,
  Chief Medical Officer
• Kevin G. Shaw,
  Sr VP, General Counsel